🇺🇸 Pneumococcal 7-valent conjugate vaccine in United States
552 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 552
Most-reported reactions
- Dyspnoea — 69 reports (12.5%)
- Asthma — 67 reports (12.14%)
- Wheezing — 65 reports (11.78%)
- Bronchiectasis — 62 reports (11.23%)
- Obstructive Airways Disorder — 60 reports (10.87%)
- Gastrooesophageal Reflux Disease — 59 reports (10.69%)
- Chronic Obstructive Pulmonary Disease — 43 reports (7.79%)
- Full Blood Count Abnormal — 43 reports (7.79%)
- Dyspnoea Exertional — 42 reports (7.61%)
- Productive Cough — 42 reports (7.61%)
Other Immunology / Infectious Disease approved in United States
Frequently asked questions
Is Pneumococcal 7-valent conjugate vaccine approved in United States?
Pneumococcal 7-valent conjugate vaccine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pneumococcal 7-valent conjugate vaccine in United States?
National Institute of Allergy and Infectious Diseases (NIAID) is the originator. The local marketing authorisation holder may differ — check the official source linked above.